Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226369 · ClinicalTrials.gov registry record · Phase 2
Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery
A Phase 2 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
NCT00226369 is a Phase 2 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 242 participants.
The verdict
NCT00226369, a Phase 2 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
Study Summary
We conducted a multicenter, randomized, placebo-controlled trial of Cylexin, an inhibitor of the attachment of white blood cells to the endothelium. Our study population was neonates and infants undergoing hypothermic cardiopulmonary bypass during surgical repair or palliation of congenital heart defects.
Interventions
- DRUG CY-1503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 1997-12 |
| Est. Completion | 2001-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226369
The ClinicalTrials.gov registry entry for NCT00226369 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CY-1503 is the first listed.
NCT00226369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226369 about?
NCT00226369 is a clinical study titled "Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery". We conducted a multicenter, randomized, placebo-controlled trial of Cylexin, an inhibitor of the attachment of white blood cells to the endothelium. Our study population was neonates and infants undergoing hypothermic cardiopulmonary bypass during surgical repair or palliation of congenital heart de...
What is the current status of trial NCT00226369?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 1997-12. Estimated completion is 2001-06.
What interventions are being tested in trial NCT00226369?
The interventions under investigation include: CY-1503 (DRUG).
Who is sponsoring clinical trial NCT00226369?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.